Cargando…

Risk factors for migraine disease progression: a narrative review for a patient-centered approach

BACKGROUND: In individuals with migraine, attacks may increase in frequency, severity, or both. Preventing migraine progression has emerged as a treatment goal in headache subspecialty practice, but there may be less awareness in general neurology or primary care settings where most people with migr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipton, Richard B., Buse, Dawn C., Nahas, Stephanie J., Tietjen, Gretchen E., Martin, Vincent T., Löf, Elin, Brevig, Thomas, Cady, Roger, Diener, Hans-Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632231/ https://www.ncbi.nlm.nih.gov/pubmed/37615752 http://dx.doi.org/10.1007/s00415-023-11880-2

Ejemplares similares

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
por: Buse, Dawn C., et al.
Publicado: (2022)

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
por: Cowan, Robert P., et al.
Publicado: (2022)

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
por: Marmura, Michael J., et al.
Publicado: (2021)

Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
por: Cady, Roger, et al.
Publicado: (2022)

Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Buse, Dawn C., et al.
Publicado: (2023)

Defining the Differences Between Episodic Migraine and Chronic Migraine
por: Katsarava, Zaza, et al.
Publicado: (2011)

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
por: Lipton, Richard B., et al.
Publicado: (2022)

Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM)
por: Lipton, Richard B, et al.
Publicado: (2015)

The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review
por: Ailani, Jessica, et al.
Publicado: (2023)

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
por: Lipton, Richard B., et al.
Publicado: (2021)

Petasites for Migraine Prevention: New Data on Mode of Action, Pharmacology and Safety. A Narrative Review
por: Borlak, Jürgen, et al.
Publicado: (2022)

Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

Patent foramen ovale and migraine: no reason to intervene
por: Diener, Hans-Christoph
Publicado: (2007)

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
por: McAllister, Peter, et al.
Publicado: (2022)

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale
por: Lipton, Richard B., et al.
Publicado: (2017)

Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention
por: Lipton, Richard B., et al.
Publicado: (2022)

Comorbid pain and migraine chronicity: The Chronic Migraine Epidemiology and Outcomes Study
por: Scher, Ann I., et al.
Publicado: (2017)

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine
por: Buse, Dawn C., et al.
Publicado: (2020)

Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine‐Associated Nausea and Prior Triptan Use on Efficacy
por: Lipton, Richard B., et al.
Publicado: (2017)

The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results
por: Adams, Aubrey Manack, et al.
Publicado: (2015)

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability
por: Lipton, Richard B., et al.
Publicado: (2016)

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Major life events, stress appraisal, and migraine: results of the American Migraine Prevalence and Prevention (AMPP) study
por: Manack, AN, et al.
Publicado: (2013)

Eptinezumab for migraine prevention in patients 50 years or older
por: Martin, Vincent, et al.
Publicado: (2022)

Content Validity of HIT‐6 as a Measure of Headache Impact in People With Migraine: A Narrative Review
por: Houts, Carrie R., et al.
Publicado: (2019)

Managing migraine by patient profile: role of frovatriptan
por: Cady, Roger K, et al.
Publicado: (2016)

Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Buse, Dawn C., et al.
Publicado: (2019)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

GERD prevalence in migraine patients and the implication for acute migraine treatment
por: Katić, Božena J., et al.
Publicado: (2008)

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2023)

Effect of fremanezumab on quality of life and productivity in patients with chronic migraine
por: Lipton, Richard B., et al.
Publicado: (2020)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study
por: Houts, Carrie R., et al.
Publicado: (2020)

Depression and risk of transformation of episodic to chronic migraine
por: Ashina, Sait, et al.
Publicado: (2012)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study
por: Schwedt, Todd J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gat1jhiuepgtfetgmfcarr6p0d